Dr Greg Neely, University of Sydney, explains how he and his team used pooled whole genome CRISPR activation screening to identify LRRC15 as a SARS-CoV-2 spike-interacting protein.
List view / Grid view
A new platform, named Virtual Synthon Hierarchical Enumeration Screening, has been developed by researchers to efficiently discover drugs.
Dr Antal Szalay, CEO and Founder of Ultimate Medicine, explores how the analysis of omics data, especially metabolomics and proteomics, can provide researchers with vital insight that can inform the development of drugs for conditions associated with age.
Here, we round up some of the key takeaways from the expert panel discussions at the Cell & Gene Therapy Advancements Online Summit.
GlaxoSmithKline (GSK) and the University of Oxford will collaborate to investigate diseases using technologies such as functional genomics and machine learning.
Scientists identify a drug candidate to minimise erratic muscle movements, called dyskinesia, associated with Parkinson’s disease.
ATH434 reversed some of the gastrointestinal damage to the enteric nervous system associated with Parkinson's disease in a pre-clinical study.
The gene therapy restored the ability of neurons to convert levodopa to dopamine and may help develop therapies to slow disease progression.
A new grant will allow an international team to determine if scent-processing nerves in the nose play a role in the development of Parkinson's and could aid in the development of novel therapeutics.
Mission Therapeutics was granted $500,000 from the The Michael J Fox Foundation for Parkinson’s Research for DUB inhibitor testing.
Scientists at the New York University (NYU) Abu Dhabi have used nuclear magnetic resonance (NMR) techniques to determine the structure of a specific nanobody, Nb23. Drug Target Review’s Victoria Rees spoke with lead researcher Professor Gennaro Esposito to find out how their findings could lead to a better understanding of…
Two different peptides were found to slow the spread of alpha-synuclein, potentially becoming the first drugs to slow the progression of Parkinson’s disease.
First-of-its-kind study uses a multi-omics approach to provide a list of causal candidate genes associated with alcohol use disorder (AUD).
Researchers have uncovered a signalling pathway associated with glutamatergic synapse degeneration in the brains of mice with Alzheimer’s.
Researchers have used fruit fly larvae to explore how alpha-synuclein impacts the mitochondria, advancing the study of Parkinson’s disease.